Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

By Ehsan Zarmina   Wetzel Jacqueline Denise   Clancy John P  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 743-749

Informa Healthcare

Access to resources Recommend Favorite

Immunomodulatory Effects of Macrolide Antibiotics in Respiratory Disease: Therapeutic Implications for Asthma and Cystic Fibrosis

By Sharma Sanjiv  

Pediatric Drugs, Vol. 9, Iss. 2, 2007-01 ,pp. : 107-118

Adis International

Access to resources Recommend Favorite

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2 - Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients

By Le Brun P.P.H.   de Boer A.H.   Mannes G.P.M.   de Frature D.M.I.   Brimicombe R.W.   Touw D.J.   Vinks A.A.   Frijlink H.W.   Heijerman H.G.M.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 54, Iss. 1, 2002-07 ,pp. : 25-32

Elsevier

Access to resources Recommend Favorite

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials

By Máiz Luis   Girón Rosa M   Olveira Casilda   Quintana Esther   Lamas Adelaida   Pastor Dolores   Cantón Rafael   Mensa Josep  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1135-1149

Informa Healthcare

Access to resources Recommend Favorite

Drug Disposition in Cystic Fibrosis

By Rey E.   Tréluyer J-M.   Pons G.  

Clinical Pharmacokinetics, Vol. 35, Iss. 4, 1998-10 ,pp. : 313-329

Adis International

Access to resources Recommend Favorite